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Abstract - The derivatives of cinnamic acid and N-arylpiperazine show antibacterial activity. In this work the potential 
synergistic effect of cinnamyl derivatives of arylpiperazine in selected bacteria was investigated. The antibacterial activities 
of the derivatives were evaluated against Gram-positive bacteria: Staphylococcus aureus, Streptosporangium longisporum, 
Sarcina lutea, Micrococcus flavus, Clostridium sporogenes and Bacillus subtilis and Gram-negative bacteria: Escherichia coli, 
Pseudomonas aeruginosa, Salmonella enteritidis and Proteus vulgaris by the disc diffusion method. The minimum inhibi-
tory concentration (MIC) against the selected bacteria was determined for all compounds that showed activity in the disc 
diffusion method. The majority of the investigated compounds displayed in vitro antibacterial activity. The effect of the 
type and structure of the substituent on the aromatic ring on the antibacterial activity is discussed. It was found that two 
derivatives expressed activity toward S. longisporum and P. aeruginosa that was almost as strong as that of amikacin.
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INTRODUCTION
Over the last 10-15 years, many pathogenic bacteria 
and parasites have become resistant to commercial 
chemotherapeutic agents. As a result, the investiga-
tion and development of potent and effective anti-
bacterial agents represent one of the most impor-
tant goals in pharmacy. However, at the moment 
only five major pharmaceutical companies, Astra 
Zeneca, GSK, Merck, Novartis and Pfizer, have ac-
tive antibacterial drug discovery programs (Škedelj 
et al., 2011). The main problem with antibacterial 
drug discovery is the low rate of approval for clinical 
use that some of them experience, as well as the re-
quired time of 8-12 years it takes for an antibiotic to 
pass from discovery to the market (Tompson et al., 
2004). Over the last 40 years only two new structural 
types of antibacterial drugs, daptomycin (lipopep-
tide in structure) and linezolid (oxazolinidone in 
structure) have been clinically used. It is well known 
that a number of heterocyclic compounds contain-
ing nitrogen and sulfur are associated with various 
types of biological activities. Piperazines and their 
analogs are a significant moiety that can be found in 
many marketed drugs, such as the Merck HIV pro-
tease inhibitor, Crixivan (Dorsey et al., 2000). Pip-
erazinyl compounds are reported as being potent 
antibacterial agents against resistant strains (Kerns 
et al., 2002), antimalarial agents (Ryckebusch et al., 
2003), dual calcium agonists (Kimura et al., 2002), 
and antipsychotic agents (Stahl and Grady, 2004). 
Also, cinnamic acid and its derivates play an impor-
tant role in antibacterial activity (Narasimhan et al., 
2004). We investigated the antibacterial activity of 
cynnamil-piperazine. All compounds reported in 
this paper were screened for their in vitro antibacte-
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rial activity against Gram-positive and Gram-nega-
tive bacterial strains using the minimum inhibitory 
concentration (MIC). 
MATERIALS AND METHODS
The antibacterial activities of cinnamic acid, 
1-(2-methoxyphenyl)-piperazine and cinnamyl de-
rivatives of arylpiperazine (Table 1) were evaluated. 
All the derivatives were synthesized by the previously 
published method (Penjišević et al., 2007).
Antibacterial investigations
The antibacterial activities of the compounds were 
evaluated against six Gram-positive bacteria: Sta-
phylococcus aureus (ATCC 6538), Streptosporangium 
longisporum (ATCC 25212), Sarcina lutea (ATCC 
9341), Micrococcus flavus (ATTC 10240), Clostrid-
ium sporogenes (ATCC 19404) and Bacillus subtilis 
(ATCC 6633) and against four Gram-negative bac-
teria: Escherichia coli (ATCC 25922), Pseudomonas 
aeruginosa (ATCC 9027), Salmonella enteritidis 
(ATCC 13076) and Proteus vulgaris (ATCC 13315).
Disc-diffusion method
A disc-diffusion method, according to the NCCLS, 
was employed for the determination of the anti-
bacterial activity of the compounds (NCCLS 1997). 
Mueller Hinton agar was prepared according to the 
instructions of the manufacturer. All agar plates were 
prepared in 90 mm Petri dishes and 100 μL of a sus-
pension of the tested microorganisms was spread on 
solid media plates. Sterile filter paper discs (6 mm in 
diameter) were impregnated with 50 µL of the sam-
ple solution in DMSO (giving 1000 μg per disc) and 
placed on inoculated plates. After standing at 4ºC 
for 2 h, the plates were incubated at 37ºC for 24 h. 
Standard discs of tetracycline (Institute of Immunol-
ogy and Virology “Torlak”: 30 μg of the active com-
ponent, diameter 6 mm) were used as a positive con-
trol, while discs imbued with 50 µL of pure DMSO 
were used as a negative control. The diameters of the 
inhibition zones (including the disc) were measured 
in millimeters. Each test was performed in triplicate.
Table 1. Structural formulae of the derivatives. 
Number Name R
1 (2E)-4-(2-methoxyphenyl)-1-(3-phenylprop-2-enyl)-piperazine H
2 (2E)-4-(2-methoxyphenyl)-1-[3-(2-methoxyphenyl)prop-2-enyl]-piperazine 2-OCH3
3 (2E)-4-(2-methoxyphenyl)-1-[3-(3-methoxyphenyl)prop-2-enyl]-piperazine 3-OCH3
4 (2E)-4-(2-methoxyphenyl)-1-[3-(4-methoxyphenyl)prop-2-enyl]-piperazine 4-OCH3
5 (2E)-4-(2-methoxyphenyl)-1-[3-(2-nitrophenyl)prop-2-enyl]-piperazine 2-NO2
6 (2E)-4-(2-methoxyphenyl)-1-[3-(3-nitrophenyl)prop-2-enyl]-piperazine 3-NO2
7 (2E)-4-(2-methoxyphenyl)-1-[3-(4-nitrophenyl)prop-2-enyl]-piperazine 4-NO2
8 (2E)-1-[3-(2-chlorophenyl)prop-2-enyl]-4-(2-methoxyphenyl)-piperazine 2-Cl
9 (2E)-1-[3-(3-chlorophenyl)prop-2-enyl]-4-(2-methoxyphenyl)-piperazine 3-Cl
10 (2E)-1-[3-(4-chlorophenyl)prop-2-enyl]-4-(2-methoxyphenyl)-piperazine 4-Cl
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Determination of the minimum inhibitory  
concentration (MIC)
The determination of the minimum inhibitory con-
centration (MIC) was performed by the broth micro-
dilution method in 96-well microtiter plates accord-
ing to the NCCLS (NCCLS 2000). Sterile 96-well 
polystyrene microtiter plates with well capacities of 
300 μl were used and 100 μl of fresh Mueler-Hin-
ton broth was added to each well of the plate. One 
hundred μL of the stock solution of the tested com-
pounds in DMSO (concentration about 2 mg/100 
μL) was added to the wells of the first column. Then 
100 μl of the solution were removed from the first 
column and mixed thoroughly with the broth in the 
corresponding wells of the second column six times. 
Subsequently, a 100 μL aliquot was removed from 
each well in this column and mixed with the broth 
in the corresponding well of the next column. This 
doubling dilution was performed in rows across the 
plate. The same procedure was repeated with stock 
solutions of each of the tested compounds. In the last 
Table 2. In vitro antibacterial activity (mm) against Gram-negative bacteria at a concentration of 1000 μg/disc.
Compound E. coli P. aeruginosa S. enteritidis P. vulgaris
1 16 14 14 -
2 22 21 22 22
3 15 14 16 -
4 15 10 19 -
5 13 10 14 -
6 17 10 15 -
7 - - - -
8 23 23 21 24
9 18 19 18 -
10 - - - -
Cinnamic acid 17 17 14 16
1-(2-Methoxyphenyl)-piperazine 18 15 15 15
Tetracycline 26 25 25 26
- inactive
a concentration 30 μg/disc
Table 3. In vitro antibacterial activity (mm) against Gram-positive bacteria at a concentration of 1000 μg/disc.
Compound S. aureus S. longisporum S. lutea M. flavus C. sporogenes B.subtilis
1 15 14 13 15 - -
2 23 24 20 24 20 22
3 16 14 16 14 - -
4 18 16 16 16 - -
5 14 13 15 20 - -
6 15 17 16 17 - -
7 - - - - - -
8 25 24 25 24 21 21
9 24 18 17 18 - -
10 - - - - - -
Cinnamic acid 14 16 19 21 14 14
1-(2-Methoxyphenyl)-
piperazine
16 15 15 15 16 15
Tetracyclinea 24 24 23 27 24 25
   - inactive
   a concentration 30 μg/disc
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row, double dilution was performed with pure DMSO 
solution and this row was used as control. Ten μL of 
the bacteria cultures was inoculated into each well of 
rows of the plate. The microtiter plate was incubated 
at 37°C for 24 h, after which the bacterial growth was 
measured. The MIC was determined as the lowest 
concentration that resulted in inhibition of bacterial 
growth. Tests were carried out in triplicate.
RESULTS AND DISCUSSION
The antibacterial activities of cinnamic acid, 
1-(2-methoxyphenyl)-piperazine and cinnamyl de-
rivatives of arylpiperazine were first tested by the 
agar disc diffusion method against Gram-positive 
and Gram-negative bacteria. The results of these 
studies, represented as zones of inhibition, are sum-
marized in Tables 2 and 3.
As can be seen from the data, both cinnamic 
acid and 1-(2-methoxyphenyl)-piperazine expressed 
activity against all investigated bacteria cells. We as-
sumed that cinnamyl derivatives of aryl-piperazine 
would exhibit antibacterial activity. It was found that 
most of the synthesized derivatives displayed in vitro 
antibacterial activity against selected bacteria. Some 
derivatives showed a better activity than the start-
ing compounds. These results indicated a potential 
synergistic antibacterial effect of synthesized deriva-
tives. Compared with compound 1, introduction of 
Table 4. The MIC value (mg/mL) of the active compounds against Gram-negative bacteria.
Compound E.coli P. aeruginosa S. enteritidis P. vulgaris
1 1.4 2.8 2.8 -
2 0.05 0.05 0.05 0.05
3 2.8 2.8 1.4 -
4 1.4 5.6 0.7 -
5 2.8 5.6 1.4 -
6 2.8 5.6 2.8 -
8 0.05 0.05 0.1 0.05
9 0.2 0.2 0.2 -
Cinnamic acid 0.36 0.36 2.88 1.44
1-(2-Methoxyphenyl)-piperazine 0.2 1.6 1.6 1.6
Amikacin 0.004 0.044 0.009 0.008
- inactive
Table 5. The MIC value (mg/mL) of the active compounds against Gram-positive bacteria.
Compound S. aureus S. longisporum S. lutea M. flavus C. sporogenes B. subtilis
1 1.4 2.8 2.8 1.4 - -
2 0.05 0.05 0.1 0.05 0.1 0.05
3 1.4 2.8 1.4 2.8 - -
4 0.7 1.4 1.4 1.4 - -
5 2.8 2.8 1.4 0.35 - -
6 2.8 1.4 2.8 1.4 - -
8 0.05 0.05 0.05 0.05 0.1 0.1
9 0.05 0.2 0.4 0.2 - -
Cinnamic acid 2.88 1.44 0.72 0.09 2.88 2.88
1-(2-Methoxyphenyl)-
piperazine
1.6 1.6 1.6 1.6 1.6 1.6
Amikacin 0.015 0.058 0.003 0.004 0.017 0.031
- inactive
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new groups in the aromatic moiety of the cinnamic 
acid in some cases provided derivatives with a better 
antibacterial activity. 
The main physiological differences between 
Gram-positive and Gram-negative bacteria are the 
structure of their cell walls. The outer layer of the 
outer membrane of Gram-negative bacteria is com-
posed primarily of lipopolysaccharide molecules, 
while a thin peptidoglycan layer is situated below the 
lipopolysaccharide layer. In this way, Gram-negative 
bacteria are protected against the effect of drugs. 
Gram-positive cell walls typically lack the out-
er membrane found in Gram-negative bacteria. In 
Gram-positive bacteria, the plasma membrane is at-
tached to the thick peptidoglycan layer. Therefore, 
these bacteria are sensitive to the effects of lysozyme 
and hydrophilic drugs. 
Since the outer layer of Gram-negative bacteria is 
negatively charged, it was expected, that most of the 
cinnamyl derivatives of arylpiperazine with delocal-
ized positive charge at the cinnamic moiety, would 
show a better activity toward Gram-negative bacte-
ria, which was indeed observed, except in the case of 
P. vulgaris. The best results were obtained by intro-
ducing substituents with positive resonance effect in 
position 2 of aromatic moiety, e.g. 2 and 8. The de-
rivative 4 possessed a moderate activity while deriva-
tives 7 and 10 did not show any antibacterial activity. 
It seems that introduction of a substituent at position 
4 afforded derivatives with weak or no antibacterial 
activity. Derivative 9 showed significant activity to-
ward most of the selected bacterial strains. The de-
rivatives with a substituent with a negative resonance 
effect on aromatic moiety, 5 and 6 expressed a weak 
activity against Gram-negative bacteria.
Against the selected Gram-positive bacteria, the 
derivatives 2 and 8 were highly active. As with the 
Gram-negative bacteria, derivative 9 expressed good 
activity. Derivatives 7 and 10 did not show any anti-
bacterial activity. Other derivatives displayed a mod-
erate activity against all selected bacteria cells, except 
C. sporogenes and B. subtilis. It was observed that, as 
in the cases of the Gram-negative bacteria, the most 
active were those derivatives that have a substitu-
ent with a positive resonance effect on the aromatic 
ring.
In the second phase, the determination of the 
MIC was performed by the broth microdilution 
method. This determination was performed with 
all derivatives that showed antibacterial activity that 
was observed in the disc diffusion method. The re-
sults are presented in Tables 4 and 5.
As can be seen from the data, the MIC values are 
in accordance with the results obtained by the disc 
diffusion method. Compound 1-(2-methoxyphenyl)-
piperazine showed a weak activity against all selected 
bacteria (1.6 mg/mL) apart from E. coli (0.2 mg/mL), 
while cinnamic acid in most cases showed a moder-
ate activity and the best activities were towards M. 
flavus, E. coli, P. aeruginosa and S. lutea (0.09-0.72 
mg/mL). Compared with these compounds, some of 
the synthesized cinnamyl derivatives of arylpipera-
zine gave a better activity against the bacteria strains. 
The most active derivatives were 2 and 8. Against 
bacteria S. longisporum and P. aeruginosa these de-
rivatives showed an in vitro activity almost as strong 
as amikacin (0.05 mg/mL). Derivative 9 expressed a 
good antibacterial activity. The range of MIC values 
for this derivative was 0.05-0.2 mg/mL. Toward both 
Gram-positive and Gram-negative bacteria, the de-
rivatives 3, 4, 5 and 6 showed weak activity, while 
against C. sporogenes, B. subtilis and P. vulgaris these 
derivatives had no activity. 
CONCLUSIONS
In this work the antibacterial activities of cinnamic 
acid, 1-(2-methoxyphenyl)-piperazine and cinnamyl 
derivatives of arylpiperazine were investigated. Most 
of the synthesized compounds displayed in vitro an-
tibacterial activity against most Gram-positive and 
Gram-negative bacteria. The best results were ob-
served for the derivatives (2E)-4-(2-methoxyphenyl)-
1-[3-(2-methoxyphenyl)prop-2-enyl]-piperazine (2) 
and (2E)-1-[3-(2-chlorophenyl)prop-2-enyl]-4-(2-
methoxyphenyl)-piperazine (8). These derivatives 
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showed the highest activity toward all investigated 
bacteria cells, while against S. longisporum and P. 
aeruginosa they had an in vitro activity which was 
almost as strong as amikacin (0.05 mg/mL). 
By comparing the antibacterial activity of all 
the synthesized derivatives, it was found that both 
the type of the substituent and its position on the 
aromatic ring had a significant impact on activity 
in bacterial strains. It was observed that position 2 
on the aromatic ring gave derivatives with the high-
est activity, while the substituent in position 4 gave 
derivatives with weak or no activity. The best results 
were obtained when in position 2 on the aromatic 
ring there were substituents with a positive resonance 
effect. The electron acceptor group, in this case the 
nitro group, decreased the general antibacterial ac-
tivity regardless of whether the group was in position 
2, 3 or 4 on the aromatic ring. It may be concluded 
that the antibacterial activity of the synthesized com-
pounds is related to the structure of the cell walls of 
the bacteria.
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